How to Antibody ingredients?

Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

34421results about "Antibody ingredients" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

InactiveUS6602684B1Increase healing valueEnhanced Fc-mediated cellular cytotoxicityNanotechFungiAntibody fragmentsADAMTS Proteins

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

View all

Owner:ROCHE GLYCART AG

Cysteine engineered antibodies and conjugates

ActiveUS7521541B2Vertebrate cellsArtificial cell constructsCross-linkDrug compound

Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I:Ab-(L-D)p Iwhere p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

Cysteine engineered antibodies and conjugates

View all

Owner:GENENTECH INC

Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

ActiveUS20050014934A1Reducing FcRn binding affinityReduced half-lifeImmunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against virusesHalf-lifeAntibody

The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and / or the serum half-life in comparison to the unmodified antibody.

Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

View all

Owner:ABBOTT BIOTHERAPEUTICS CORP

Polypeptide variants with altered effector function

InactiveUS7371826B2High affinityHigh activityFungiVirusesAmino acidEffector functions

The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.

Polypeptide variants with altered effector function

View all

Owner:GENENTECH INC

Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases

PendingUS20060104968A1Improve extentIncrease ratingsSenses disorderNervous disorderHyaluronidaseRecombinant glycoprotein

The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases

View all

Owner:HALOZYME

Antibodies to human programmed death receptor PD-1

ActiveUS8354509B2Increased activationIncreased proliferationSugar derivativesAntibody ingredientsProgrammed deathReceptor for activated C kinase 1

Antibodies which block the binding of human Programmed Death Receptor 1 (hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.

Antibodies to human programmed death receptor PD-1

View all

Owner:MERCK SHARP & DOHME BV

Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

ActiveUS20050260186A1Improve extentIncrease ratingsAntibacterial agentsSenses disorderHyaluronidasePathology diagnosis

View all

Owner:HALOZYME

Anti-PD-L1 antibodies, compositions and articles of manufacture

ActiveUS8217149B2Antibacterial agentsOrganic active ingredientsT-cell dysfunctionPD-L1

The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Anti-PD-L1 antibodies, compositions and articles of manufacture

View all

Owner:F HOFFMANN LA ROCHE & CO AG

Humanized anti-TGF-beta antibodies

ActiveUS7527791B2Nervous disorderAntipyreticHumanized antibodyAntibody

Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.

View all

Owner:GENENTECH INC

Multispecific antibodies

ActiveUS20080069820A1High binding affinityHigh affinityImmunoglobulins against growth factorsAntibody ingredientsSpecific antibody

The invention provides multispecific antibodies and methods of making and using such antibodies.

View all

Owner:GENENTECH INC

Multivalent antibodies and uses therefor

InactiveUS20060025576A1Easy to produceFungiBacteriaBinding siteAntigen binding

The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.

Multivalent antibodies and uses therefor

View all

Owner:GENENTECH INC

Monomethylvaline compounds capable of conjugation to ligands

ActiveUS20050238649A1Improve bioavailabilityImprove compoundAntibacterial agentsBiocideD-norephedrineBiochemistry

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

Monomethylvaline compounds capable of conjugation to ligands

View all

Owner:SEAGEN INC

Human CTLA-4 antibodies

ActiveUS6984720B1Improve toleranceAntibacterial agentsNervous disorderHuman sequenceCTLA4 Protein

The present invention provides human sequence antibodies against CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.

View all

Owner:ER SQUIBB & SONS INC

PD-1 binding proteins

ActiveUS8168757B2Regulating T cell responsesImprove immunityAntibody mimetics/scaffoldsAntibody ingredientsHost immunitySignalling pathways

The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.

View all

Owner:MERCK SHARP & DOHME LLC

Variable domain library and uses

ActiveUS20050266000A1Generate efficientlyQuality improvementImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsComplementarity determining regionAntigen binding

The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may optionally comprise one or more complementary determining regions (CDRs) of antibody variable domains. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR and one or more variant CDRs. Libraries of polypeptides that include a plurality of different antibody variable domains generated by creating diversity in a VFR, and optionally, one or more CDRs are provided and may be used as a source for identifying novel antigen binding polypeptides that can be used therapeutically or as reagents. The invention also provides fusion polypeptides, compositions, and methods for generating and using the polypeptides and libraries.

View all

Owner:GENENTECH INC

Simultaneous stimulation and concentration of cells

InactiveUS6867041B2Maximizes stimulationCulture processArtificial cell constructsDrug discoveryCells signal

The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and / or stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.

Simultaneous stimulation and concentration of cells

View all

Owner:LIFE TECH CORP

Binding polypeptides with restricted diversity sequences

InactiveUS20070237764A1Small sizeHigh-quality target binding characteristicFermentationVector-based foreign material introductionHeterologousAntigen binding

The invention provides variant CDRs comprising highly restricted amino acid sequence diversity. These polypeptides provide a flexible and simple source of sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.

Binding polypeptides with restricted diversity sequences

View all

Owner:GENENTECH INC

Binding polypeptides with diversified and consensus vh/vl hypervariable sequences

ActiveUS20070160598A1Raise the possibilitySmall sizeAnimal cellsSugar derivativesAntibody hypervariable regionBioinformatics

The invention provides variant hypervariable regions comprising selected amino acid sequence diversity. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.

Binding polypeptides with diversified and consensus vh/vl hypervariable sequences

View all

Owner:GENENTECH INC

Methods for selectively stimulating proliferation of T cells

InactiveUS7175843B2Increase the number ofBiocideCell receptors/surface-antigens/surface-determinantsAccessory moleculeExogenous growth

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR) / CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Methods for selectively stimulating proliferation of T cells

View all

Owner:GENETICS INST LLC +2

Drug depot implant designs

ActiveUS7727954B2Uniform drug distributionMinimal disruptionPowder deliveryPeptide/protein ingredientsSkeletal injuryChronic pain

The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.

View all

Owner:WARSAW ORTHOPEDIC INC

Molecules with extended half-lives, compositions and uses thereof

InactiveUS7083784B2Compounds screening/testingFungiHalf-lifeIn vivo

The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

Molecules with extended half-lives, compositions and uses thereof

View all

Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1

Wound closure material

InactiveUS20100076489A1Prevent leakageSuture equipmentsHeavy metal active ingredientsButtressBiomedical engineering

Articles are provided having no orientation or a multi-directional orientation. Such articles may be in the form of films, ribbons, sheets, and / or tapes and may be utilized as buttresses with a surgical stapling apparatus or as reinforcing means for suture lines. The articles may be produced with a polymeric material having an agent, such as a chemotherapeutic agent or a radiotherapeutic agent, incorporated therein or applied as a coating thereon.

View all

Owner:TYCO HEALTHCARE GRP LP

Methods for selectively stimulating proliferation of T cells

InactiveUS7144575B2Increase the number ofBiocidePeptide/protein ingredientsAccessory moleculeExogenous growth

View all

Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY +2

Nucleic acids encoding chimeric T cell receptors

ActiveUS7446190B2Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsCytotoxicityBiological activation

Chimeric T cell receptors (TCR) are provided that combine, in a single chimeric species, the intracellular domain of CD3 ζ-chain, a signaling region from a costimulatory protein such as CD28, and a binding element that specifically interacts with a selected target. When expressed, for example in T-lymphocytes from the individual to be treated for a condition associated with the selected target, a T cell immune response is stimulated in the individual to the target cells. The chimeric TCR's are able to provide both the activation and the co-stimulation signals from a single molecule to more effectively direct T-lymphocyte cytotoxicity against the selected target and T-lymphocyte proliferation.

Nucleic acids encoding chimeric T cell receptors

View all

Owner:SLOAN KETTERING INST FOR CANCER RES

Activation and expansion of cells

InactiveUS20060121005A1BiocideMammal material medical ingredientsHigh densityBiological activation

The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and / or stimulate cells that maximizes the expansion of such cells to achieve dramatically high densities. In the various embodiments, cells are activated and expanded to very high densities in a short period of time. In certain embodiments, cells are activated and expanded to very high numbers of cells in a short period of time. Compositions of cells activated and expanded by the methods herein are further provided.

View all

Owner:LIFE TECH CORP

Human antibodies that bind human IL-12 and methods for producing

InactiveUS6914128B1Avoid interferencePreservationNervous disorderPeptide/protein ingredientsAntigen bindingIn vivo

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human IL-12 and methods for producing

View all

Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Method of treating androgen independent prostate cancer

InactiveUS9040574B2BiocideCarbohydrate active ingredientsProstate cancer cellDiketone

The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and / or metastasis of prostate cancer cells.

Method of treating androgen independent prostate cancer

View all

Owner:NATROGEN THERAPEUTICS INT

Anti-PD-L1 antibodies and uses therefor

ActiveUS8552154B2Antibacterial agentsAntipyreticTransplant rejectionAutoimmune disease

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and / or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

View all

Owner:DANA FARBER CANCER INST INC +2

Compositions of pd-1 antagonists and methods of use

InactiveUS20120114649A1Improve responseInhibitory signal transductionAntibacterial agentsOrganic active ingredientsT cellInfective disorder

Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.

Compositions of pd-1 antagonists and methods of use

View all

Owner:MEDIMMUNE LLC

Cytotoxic agents comprising new maytansinoids

ActiveUS7276497B2Improve anti-tumor activityImprove biological activityOrganic active ingredientsOrganic chemistryAnimal tumorEfficacy

New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

Cytotoxic agents comprising new maytansinoids

View all

Owner:IMMUNOGEN INC

34421results about "Antibody ingredients" patented technology

Popular searches